In an exploratory subgroup analysis in the phase 3 IMpower150 study, the VEGF inhibitor bevacizumab and the PD-L1 inhibitor atezolizumab combined with chemotherapy were clinically effective in patients with tyrosine kinase inhibitor-treated advanced-stage EGFR mutation- or ALK rearrangement-positive NSCLC [8, 17]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.